{"id":164206,"date":"2014-12-05T12:52:18","date_gmt":"2014-12-05T17:52:18","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/why-cll-there-are-often-relapses-after-treatment.php"},"modified":"2014-12-05T12:52:18","modified_gmt":"2014-12-05T17:52:18","slug":"why-cll-there-are-often-relapses-after-treatment","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/molecular-medicine\/why-cll-there-are-often-relapses-after-treatment.php","title":{"rendered":"Why CLL there are often relapses after treatment"},"content":{"rendered":"<p><p>    PUBLIC RELEASE DATE:  <\/p>\n<p>    5-Dec-2014  <\/p>\n<p>    Contact: Barbara Bachtler    <a href=\"mailto:bachtler@mdc-berlin.de\">bachtler@mdc-berlin.de<\/a>    49-309-406-3896    Max Delbrueck Center for Molecular    Medicine (MDC) Berlin-Buch  <\/p>\n<p>    Chronic lymphocytic leukemia (CLL) is among the most frequent    leukemias affecting adults in Western countries. It usually    occurs in older patients, does not cause any symptoms for a    long time and is often only discovered by accident. Despite    treatment, relapses frequently occur. The immunologists Dr.    Kristina Heinig and Dr. Uta Hpken (Max Delbrck Center for    Molecular Medicine, MDC, Berlin-Buch) and the hematologist Dr.    Armin Rehm (MDC and Charit - Universittsmedizin Berlin) have    now discovered why this is so. In a mouse model they developed,    the researchers demonstrated that crosstalk between the cancer    cells and a group of stromal cells in the spleen is crucial for    cancer growth. At the same time they were able to block the    entry of cancer cells into the spleen as well as their    proliferation and thus identified new targets for future    therapies in humans (Cancer    Discovery, doi: 10.1158\/2159-8290.CD-14-0096).*  <\/p>\n<p>    A high number of malignantly mutated B lymphocytes is    characteristic for CLL. B cells are normally an important    component of the immune system. They produce antibodies with    which the body combats pathogens (foreign antigens) and    pathogenically modified structures. They acquire their final    functionality in the germinal centers of lymphoid organs such    as the spleen.  <\/p>\n<p>    For this purpose, the healthy B cells migrate into the B-cell    zone (B-cell follicle) of the spleen and lodge there in the    stromal cell niche. There they interact with follicular    dendritic cells (FDC). Unlike the similarly named classical    dendritic cells, the FDC are not blood cells but rather stromal    cells that form a network in the center of the B cell follicle.    This stromal cell network lures B cells into it and exposes    them to foreign antigens, which the B cells recognize and    require for their activation and maturation. Only then are they    fit for their task as antibody-producing immune cells.  <\/p>\n<p>    The B cells enter the \"training center\" of the lymphoid organs    via the messenger molecules of the immune system, the    chemokines. They guide the B lymphocytes, which have a receptor    on their surface for these chemokines. Leukemia cells, as    malignant immune cells, also have these homing receptors on    their cell surface to which these chemokines bind, thus    enabling them to establish themselves in the stromal cell    niche.  <\/p>\n<p>    In their research project, Dr. Hpken and Dr. Rehm started from    the hypothesis that the processes which normally regulate the    migration of B lymphocytes into the B-cell follicle are also    the reason for the migration of leukemia cells into the    lymphoid organs. Hence, within the B-cell follicle the survival    and growth of malignant B cells may depend on the contact of    the leukemia cells with the FDC.  <\/p>\n<p>    In CLL, despite chemotherapy or radiotherapy, a relapse with    renewed leukemic proliferation in lymphoid tissues can occur    because the FDC usually survive chemotherapy or radiotherapy    far better than the leukemia cells. If a few leukemia cells    escape the therapy - physicians call this minimal residual    disease - the FDC ensure that the leukemia cells within the    B-cell follicles have optimal growth conditions and    proliferate. Dr. Heinig, Dr. Hpken and Dr. Rehm have now    elucidated this process in detail in a mouse model, which is    similar to human CLL.  <\/p>\n<p>    Intensive interaction between leukemia cells and the FDC  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>See original here: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.eurekalert.org\/pub_releases\/2014-12\/mdcf-wct120514.php\/RK=0\/RS=skylThtktcDk8U.poHTI3zWJA5c-\" title=\"Why CLL there are often relapses after treatment\">Why CLL there are often relapses after treatment<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> PUBLIC RELEASE DATE: 5-Dec-2014 Contact: Barbara Bachtler <a href=\"mailto:bachtler@mdc-berlin.de\">bachtler@mdc-berlin.de<\/a> 49-309-406-3896 Max Delbrueck Center for Molecular Medicine (MDC) Berlin-Buch Chronic lymphocytic leukemia (CLL) is among the most frequent leukemias affecting adults in Western countries. It usually occurs in older patients, does not cause any symptoms for a long time and is often only discovered by accident <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/molecular-medicine\/why-cll-there-are-often-relapses-after-treatment.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[26],"tags":[],"class_list":["post-164206","post","type-post","status-publish","format-standard","hentry","category-molecular-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/164206"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=164206"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/164206\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=164206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=164206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=164206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}